HRs for Parkinson’s disease among patients with diabetes mellitus during a 5-year follow-up period, stratified by pioglitazone cumulative dose
| Following incidence of Parkinson’s disease | Pioglitazone cumulative dose | ||
| ≥365 cDDD (n=3957) | <365 cDDD (n=3949) | 0 cDDD (n=3957) | |
| Five-year follow-up period | |||
| Yes, n (%) | 55 (1.39) | 64 (1.62) | 138 (1.75) |
| Crude HR (95% CI) | 0.79 (0.58 to 1.09) | 0.93 (0.69 to 1.25) | 1.00 |
| Adjusted HR* (95% CI) | 0.94 (0.66 to 1.34) | 0.82 (0.59 to 1.15) | 1.00 |
*Adjusted for age, sex, geographical region, urbanisation level, monthly income, hypertension, hyperlipidaemia, depressive disorder, insomnia, stroke, head injury, aspirin use, statins use and angiotensin receptor blockers use.
cDDD, cumulative defined daily dose.